TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact

Pipeline

Transcenta is developing a pipeline of nine innovative molecules for the treatment of cancer, bone and kidney disorders.

Oncology
Drugs
Candidate
Target
Pathway
Indication
Clinical Trial
Region
Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Rights
Partner
MSB2311
PD-L1
Validated
TMB-H Solid Tumors
Solid Tumors
Solid Tumors
Solid Tumors
China
China
China
United States
MSB2311
More + More +

Drugs Candidate:PD-L1

Pathway:Validated

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
TMB-H Solid Tumors -China - Monotherapy
Monotherapy
Solid Tumors -China - Monotherapy
Monotherapy
Solid Tumors -China - Combo with VEGFRi
Combo with VEGFRi
Solid Tumors -United States - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST001
Claudin 18.2
Partially Validated
Solid Tumors
Late-line Gastric Cancer
Second-line Gastric Cancer
First-line Gastric Cancer
Other Solid Tumors
Global
China
Global
Global
Global
TST001
More + More +

Drugs Candidate:Claudin 18.2

Pathway:Partially Validated

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -Global - Monotherapy
Monotherapy
Late-line Gastric Cancer -China - Monotherapy
Monotherapy
Second-line Gastric Cancer -Global - Combo with Chemo
Combo with Chemo
First-line Gastric Cancer -Global - Combo with Chemo
Combo with Chemo
Other Solid Tumors -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST005
PD-L1/TGF-β Bi-functional
Partially Validated
Solid Tumors (HPV+ and NSCLC, etc.)
Global
TST005
More + More +

Drugs Candidate:PD-L1/TGF-β Bi-functional

Pathway:Partially Validated

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors (HPV+ and NSCLC, etc.) -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
MSB0254
VEGFR2
Validated
Solid Tumors
China
MSB0254
More + More +

Drugs Candidate:VEGFR2

Pathway:Validated

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -China - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST003
BMP Antagonist (FIC)
Novel
Solid Tumors
Global
TST003
More + More +

Drugs Candidate:BMP Antagonist (FIC)

Pathway:Novel

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST006
Claudin 18.2/PD-L1 Bi-specific (FIC)
Novel
Solid Tumors
Global
TST006
More + More +

Drugs Candidate:Claudin 18.2/PD-L1 Bi-specific (FIC)

Pathway:Novel

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
Non-oncology
Drugs
Candidate
Target
Pathway
Indication
Clinical Trial
Region
Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Rights
Partner
TST002
Sclerostin
Validated
Osteoporosis
China
TST002
More + More +

Drugs Candidate:Sclerostin

Pathway:Validated

Right:Greater China

Partner:In-licensed from Eli Lilly

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
PH 2b/PH 3
Osteoporosis -China - Monotherapy
Monotherapy
Greater China
In-licensed from Eli Lilly
READ MORE READ MORE
TST004
MASP2
Partially Validated
TMA/IgA Nephropathy
Global
TST004
More + More +

Drugs Candidate:MASP2

Pathway:Partially Validated

Right:Global

Partner:Co-development with Alebund in Greater China

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
PH 2b/PH 3
TMA/IgA Nephropathy -Global - Monotherapy
Monotherapy
Global
Co-development with Alebund in Greater China
READ MORE READ MORE
TST008
MASP2+ Tri-functional (FIC)
Novel
SLE
Global
TST008
More + More +

Drugs Candidate:MASP2+ Tri-functional (FIC)

Pathway:Novel

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
PH 2b/PH 3
SLE -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TOP
肿瘤

MSB2311*

靶点:PD-L1

适应症:TMB-H 实体瘤

临床实验地区:中国

权利:全球

合伙人:内部

MSB2311 是靶向结合 PD-L1 的研究性 pH 依赖性人源化抗体。

PD-L1 参与抑制了对抗癌症的免疫系统应答,在实体瘤患者的肿瘤细胞中PD-L1表达水平显著升高。MSB2311 使用了工程改造去除了和Fc受体结合的人源IgG1。MSB2311 可与肿瘤细胞上的 PD-L1 结合,并阻断 PD-L1 和 PD-1(T效应细胞上的受体)的相互作用。此外,MSB2311 与 PD-L1 的结合引发 MSB2311 的内吞,当进入 pH 值低于5.5 的核内体时,MSB2311 可从结合的 PD-L1 上分离, MSB2311 可在 FcRn 的帮助下再循环到质膜,并重新与其他肿瘤细胞上的 PD-L1 结合。临床前研究结果表明,MSB2311 在同源小鼠模型中可抑制有表达 PD-L1 的肿瘤细胞的肿瘤生长。